Publications by authors named "Archibald Prentice"

Claim this Profile
I
Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.
Simone Lanini, Aoife C Molloy, Archibald G Prentice, Giuseppe Ippolito, Christopher C Kibbler

BMC Infect Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.
R Gitendra Wickremasinghe, Archibald G Prentice, Andrew J Steele

Br J Haematol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.
Simone Lanini, Aoife C Molloy, Paul E Fine, Archibald G Prentice, Giuseppe Ippolito

BMC Med· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.
Andrew J Steele, Archibald G Prentice, Kate Cwynarski, A Victor Hoffbrand, Stephen M Hart

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients undergoing high dose chemotherapy for primary CNS lymphoma should receive prophylactic thiamine to prevent Wernike's encephalopathy.
Simon Richardson, Anmol Malhotra, Kate Cwynarski, Derralynn Hughes, Archibald Prentice

Br J Haematol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Alan K Burnett, Robert K Hills, Claire Green, Sarah Jenkinson, Kenneth Koo, Archibald G Prentice

Blood· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Alan K Burnett, Robert K Hills, Donald W Milligan, Anthony H Goldstone, Archibald G Prentice

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Andrew J Steele, Archibald G Prentice, A Victor Hoffbrand, Birunthini C Yogashangary, Stephen M Hart

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.
Keith Wheatley, Cassandra L Brookes, Andrew J Howman, Anthony H Goldstone, Donald W Milligan, Archibald G Prentice

Br J Haematol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Alan K Burnett, Donald Milligan, Anthony Goldstone, Archibald Prentice, Mary-Frances McMullin

Br J Haematol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Andrew J Steele, Archibald G Prentice, A Victor Hoffbrand, Birunthini C Yogashangary, Stephen M Hart

Blood· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Sarah J Richardson, Christine Matthews, Mark A Catherwood, H Denis Alexander, B Sean Carey, Archibald G Prentice

Blood· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making sense of itraconazole pharmacokinetics.
Archibald Grant Prentice, Axel Glasmacher

J Antimicrob Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Axel Glasmacher, Archibald Grant Prentice

J Antimicrob Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
Axel Glasmacher, Archibald Prentice, Marcus Gorschlüter, Steffen Engelhart, Corinna Hahn

J Clin Oncol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis